パトコア Official site

Patcore Inc. (Headquarters: Tokyo) has partnered with Chemical.AI (USA/China), a global leader in AI technology for chemical synthesis route design, to begin domestic provision of the AI retro-synthesis platform "ChemAIRS." ChemAIRS is a platform where AI, equivalent to skilled chemists with over 10 years of experience, can automatically propose complex synthesis routes in just a few minutes. It enables the identification of chirality introduction risks, prediction of side reactions and impurities, and the design of highly feasible routes considering raw material availability, yield, and cost. Additionally, it seamlessly integrates with Chemaxon's "Design Hub," for which Patcore serves as the exclusive domestic distributor, accelerating the DMTA cycle in a one-stop manner. Currently, we are accepting applications for a two-week free trial. For more details about the product and to apply, please contact us through Patcore Inc.'s official website. ▶ Two-week free trial now available Try out its capabilities with the challenges in your research lab. ▼ ChemAIRS product page: https://patcore.com/product/chemairs

In drug discovery research utilizing AI and machine learning, the biggest factor influencing the accuracy of predictive models is "data quality." Excelra and Patcore will co-host a free online webinar on the theme of GOSTAR(TM), which accelerates AI drug discovery, on June 11, 2026, at 13:30. Utilizing GOSTAR(TM), one of the world's largest manually curated SAR databases, the webinar will explain, with live demonstrations, the acceleration of predictive modeling using ML-ready data, improvements in molecular design accuracy in medicinal chemistry, and the establishment of a data foundation that supports go/no-go decisions from lead optimization. The speaker will be Dr. Nishanth Kandepedu from Excelra, who has over 10 years of experience in the drug discovery field. Researchers in drug discovery from pharmaceutical and biotech companies, AI/ML engineers, and R&D leaders are widely invited to participate. Participation is free, but prior registration is required. Registration will close once capacity is reached. ▼Details & Registration: https://patcore.com/news/webinar-gostar-2026

Excelra has announced a partnership with Patcore to provide Japanese customers access to Excelra's scientific data and analytics products. Excelra is one of the world's leading companies in data and digital insights. Its GOSTAR platform is the largest manually curated medicinal chemistry information database, offering comprehensive and structured SAR (structure-activity relationship) data on over 9 million compounds. Excelra's GOBIOM includes the most extensive manually curated collection of verified and estimated biomarkers, providing critical insights into the relationship between biomarkers (biological indicator compounds) and diseases. Patcore is a highly specialized informatics company that supports researchers in the life sciences and chemical industries. This partnership leverages Patcore's strengths, which include experience working with some of Japan's largest pharmaceutical companies, biotechnology firms, chemical companies, and government agencies, to support Excelra's growth in Japan. For more details, please visit our website at the link below.

Chemical.AI, a global leader in artificial intelligence (AI) for synthetic route design and prediction, and Chemaxon, a leading company in chemical and biological software development, have announced a strategic partnership that will allow access to Chemical.AI's reverse synthesis tool, ChemAIRS, as an option from Chemaxon's drug discovery platform, Design Hub. This collaboration creates compatibility between Chemical.AI's ChemAIRS and Chemaxon's Design Hub, enabling a seamless user workflow and one-stop service that integrates compound design tracking and prioritization features from Design Hub with the innovative synthetic routes generated in minutes using ChemAIRS's diverse strategies. For more details, please visit our website.

Chemaxon, a leader in the development of cheminformatics software for life sciences research, has announced the appointment of Richard Jones as Chief Executive Officer (CEO). Richard succeeds the owner, Ferenc (Csizi) Csizmadia, in this role. Csizi will continue to serve as a founder while focusing on the establishment of Ancestralize, which is centered on health and well-being in the digital age. Additionally, coinciding with Mr. Richard's appointment, Chemaxon's Budapest office has relocated to the newly constructed environmentally friendly office park, Váci Greens, on the east side of the Danube River. A new logo and spelling have also been announced. For more details, please visit the news article on our company's homepage via the link below.